Welcome to our dedicated page for Tvardi Therapeutics SEC filings (Ticker: TVRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tvardi Therapeutics, Inc. (NASDAQ: TVRD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tvardi’s filings describe it as a Delaware corporation and a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.
Through documents such as Form 8-K current reports, investors can review Tvardi’s announcements regarding financial results, business updates, executive and director changes, compensation arrangements, and key clinical and corporate events. Recent 8-K filings have covered quarterly results, updates on preliminary data from the REVERT IPF Phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis, the availability of updated corporate presentations, and the adoption of a severance and change in control plan and retention equity awards for certain employees.
Registration statements on Form S-1/A offer additional detail on Tvardi’s business following its merger with Legacy Tvardi, the change of name from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc., and the commencement of trading on The Nasdaq Capital Market under the symbol TVRD. These filings also outline the company’s status as a smaller reporting company and its focus on STAT3-targeted clinical programs, including TTI-101 and TTI-109.
On Stock Titan, Tvardi’s SEC filings are updated as new documents are posted to EDGAR, and AI-powered summaries can help explain the key points in lengthy filings such as registration statements and current reports. Users can quickly identify items related to clinical trial disclosures, capital structure, compensation plans, and other material events, and can also monitor how Tvardi describes the progress and risks associated with its STAT3 inhibitor programs over time.
Tvardi Therapeutics, Inc. filed a prospectus supplement covering the resale by certain selling stockholders of up to 2,084,117 shares of common stock issued under the December 17, 2024 Merger Agreement with Cara Therapeutics. The supplement updates the base prospectus with information from the company’s Q3 2025 Form 10‑Q.
The common stock trades on Nasdaq as “TVRD.” The last quoted sale price on November 12, 2025 was $4.24. Shares outstanding were 9,381,344 as of November 10, 2025.
The attached 10‑Q reports a net loss of $5.5 million for the quarter and $10.9 million for the nine months ended September 30, 2025, cash and cash equivalents of $21.4 million and short‑term investments of $15.0 million. Management states that conditions raise substantial doubt about the company’s ability to continue as a going concern. The 10‑Q also notes preliminary Phase 2 data in IPF for TTI‑101 did not meet study goals, with further analyses ongoing.
Tvardi Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results and business highlights for the fiscal quarter ended September 30, 2025. The company issued the press release on November 13, 2025, and attached it as Exhibit 99.1.
The information about results and highlights is furnished under Item 2.02 of the Exchange Act and is not deemed filed or incorporated by reference into other SEC filings. The report also includes an Inline XBRL cover page as Exhibit 104.
Tvardi Therapeutics (TVRD) filed its Q3 2025 report, showing a net loss of $5.5 million for the quarter. Operating expenses were driven by research and development of $3.6 million and general and administrative of $2.3 million. Interest income was $0.4 million.
Liquidity remains a key focus. The company reported cash and cash equivalents of $21.4 million and short‑term investments of $15.0 million as of September 30, 2025. Cash used in operating activities was $17.8 million for the nine months. Management disclosed conditions that raise substantial doubt about the company’s ability to continue as a going concern.
Tvardi completed a reverse recapitalization with Cara Therapeutics on April 15, 2025, adding $24.992 million of cash and converting the company’s Convertible Notes into 1,265,757 shares, with a $7.8 million fair value gain recognized year‑to‑date. A subsequent event noted that the Phase 2 IPF study of TTI‑101 did not meet its goals on October 13, 2025. Common shares outstanding were 9,381,344 as of November 10, 2025.
Tvardi Therapeutics, Inc. filed a Form S-8 to register shares for employee equity plans. The filing registers 715,934 shares of common stock under the 2018 Stock Incentive Plan, 935,554 shares under the 2025 Equity Incentive Plan, and 93,555 shares under the 2025 Employee Stock Purchase Plan.
The company explains that on April 15, 2025, Cara Therapeutics, Inc. completed a merger with Tvardi, after which Cara changed its name to Tvardi Therapeutics, Inc. and assumed Tvardi’s 2018 Plan. Outstanding Legacy Tvardi stock options were converted into options to purchase Tvardi Therapeutics common stock.
The filing also outlines director and officer indemnification provisions under Delaware law and references governing corporate documents and plan exhibits incorporated by reference.
Tvardi Therapeutics (TVRD) filed Amendment No. 2 to a Form S-1 to register the resale of up to 2,084,117 shares of common stock issued to certain holders in connection with its April 2025 merger. The company states it will not receive any proceeds from sales under this prospectus; selling stockholders will pay any commissions and discounts.
The shares may be sold from time to time using various methods and prices. Tvardi’s common stock trades on Nasdaq as TVRD; the last quoted sale price was $6.58 on October 17, 2025. Following the merger and a 1‑for‑3 reverse stock split, 9,355,542 shares were issued and outstanding immediately after the effective time.
Tvardi is a clinical‑stage biopharma developing oral STAT3 inhibitors. Lead candidate TTI‑101 is in Phase 2 for HCC with FDA Fast Track and orphan designations; the company reported preliminary Phase 2 IPF data in October 2025 and concluded the study did not meet its goals. Risk disclosures note substantial doubt about the company’s ability to continue as a going concern and the need for additional capital.
Tvardi Therapeutics, Inc. (TVRD) filed a Form 8-K announcing a press release about preliminary data from its Phase 2 REVERT trial in idiopathic pulmonary fibrosis. The company stated the full text of the press release, titled “Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis,” is furnished as Exhibit 99.1 and incorporated by reference.
Tvardi Therapeutics (TVRD) filed an amended S-1 that stresses the company is an early-stage clinical biotechnology company with no product revenue, an accumulated deficit of $92.2M and cash resources that management deems insufficient to fund operations for at least one year, creating substantial doubt about its ability to continue as a going concern. The filing describes lead programs TTI-101 (oral STAT3 inhibitor) and TTI-109, development plans in IPF and HCC, regulatory designations (orphan and Fast Track for TTI-101 in select indications), and trial timelines: a 12-week REVERT IPF Phase 2 study (38 randomized patients) with preliminary blinded data showing ~50% of participants near or above baseline FVC and an expected unblinded readout in Q4 2025, and a REVERT HCC Phase 1b/2 program with preliminary topline data expected in H1 2026. The company disclosed material financing instruments: Convertible Notes with $28.3M principal (fair-valued to $30.1M at year-end), 8% interest, and conversion mechanics tied to Qualified Financings, an IPO, or a reverse merger. The S-1/A also describes the Merger that converted Legacy Tvardi equity into Cara shares, acquisition of approximately $23.9M in net assets, historical financings including Series A ($8.4M) and Series B ($66.3M), identified material weaknesses in legacy internal controls, and broad risk factors tied to clinical, regulatory, manufacturing, IP and commercialization challenges.
Tvardi Therapeutics, Inc. filed a Form 8-K to furnish a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The company, formerly known as Cara Therapeutics, issued the release on August 14, 2025, and attached it as Exhibit 99.1.
The disclosure is provided under Item 2.02, "Results of Operations and Financial Condition," and is expressly described as being "furnished" rather than "filed," which limits its applicability for certain securities law liability provisions and for automatic incorporation by reference into other SEC filings.
Slate Path Capital LP and David Greenspan report owning 704,118 shares (7.5%) of Tvardi Therapeutics (TVRD). The holdings are held by Slate Path Master Fund LP and SPB Master Fund LP and are reported as shared voting and dispositive power; neither reporting person claims sole voting or dispositive power. The percentage is calculated using 9,360,904 shares outstanding as of May 8, 2025. The filing states the shares were acquired in the ordinary course of business and were not acquired to change or influence control of the company.
Sporos Bioventures LLC reported direct beneficial ownership of 837,636 shares of Tvardi Therapeutics common stock, equal to 8.95% of the outstanding class. The filer discloses sole voting power and sole dispositive power over these shares, and reports no shared voting or dispositive arrangements.
This Schedule 13G statement records a material, reportable passive stake above the 5% threshold and provides investors with clear disclosure of concentrated ownership and voting control of a meaningful minority position in TVRD.